Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study
Pett, Sarah Lilian, Amin, Janaki, Horban, Andrejz, Andrade-Villanueva, Jaime, Losso, Marcelo, Porteiro, Norma, Madero, Juan Sierra, Belloso, Waldo, Tu, Elise, Silk, David, Kelleher, Anthony, Harrigan, Richard, Clark, Andrew, Sugiura, Wataru, Wolff, Marcelo, Gill, John, Gatell, Jose, Fisher, Martin, Clarke, Amanda, Ruxrungtham, Kiat, Prazuck, Thierry, Kaiser, Rolf, Wolley, Ian, Arnaiz, Juan Alberto, Cooper, David, Rockstroh, Jürgen K., Mallon, Patrick, Emery, Sean
Published in Clinical infectious diseases (01.07.2016)
Published in Clinical infectious diseases (01.07.2016)
Get full text
Journal Article